Making Pain Relief Affordable – Or Abuse Cheaper?
This article was originally published in RPM Report
Executive Summary
There are many arguments against generics of opioids, especially if you’re Purdue Pharma. Here’s a new one: they’re lower the cost for abusers.
You may also be interested in...
DEA Delays in Scheduling Are Offsetting FDA’s Improved Decision Making
FDA is showing a renewed commitment to meeting review deadlines for new molecular entities, but that is not translating into earlier commercial availability for all NMEs. Some products also need a controlled substance scheduling decision from the Drug Enforcement Administration; those actions have become a new regulatory purgatory that can be painful and frustrating.
US FDA Exploring Options To Improve Study Of Drugs In Elderly
New incentives will most likely not be the immediate focus, but working group to explore ideas on enhancing understanding of drug effects in elderly populations will likely be formed by US FDA.
Not So Fast: Trump Team Paints US FDA Review Times As Too Slow
New ‘statement of policy’ directs US FDA to publish charts of its approval timeliness – using an outdated 180-day benchmark to make its approval speed look worse.